APA
Click to copy
Zhang, Q., Ni, Y., Wang, S., Agbana, Y. L., Han, Q., Liu, W., … Zhu, Y. (2020). G6PD upregulates Cyclin E1 and MMP9 to promote clear cell renal cell carcinoma progression. International Journal of Medical Sciences.
Chicago/Turabian
Click to copy
Zhang, Qiao, Yueli Ni, Shujie Wang, Yannick Luther Agbana, Qiaoqiao Han, Wenjing Liu, Honggang Bai, et al. “G6PD Upregulates Cyclin E1 and MMP9 to Promote Clear Cell Renal Cell Carcinoma Progression.” International Journal of Medical Sciences (2020).
MLA
Click to copy
Zhang, Qiao, et al. “G6PD Upregulates Cyclin E1 and MMP9 to Promote Clear Cell Renal Cell Carcinoma Progression.” International Journal of Medical Sciences, 2020.
BibTeX Click to copy
@article{qiao2020a,
title = {G6PD upregulates Cyclin E1 and MMP9 to promote clear cell renal cell carcinoma progression},
year = {2020},
journal = {International Journal of Medical Sciences},
author = {Zhang, Qiao and Ni, Yueli and Wang, Shujie and Agbana, Yannick Luther and Han, Qiaoqiao and Liu, Wenjing and Bai, Honggang and Yi, Zihan and Yi, X. and Zhu, Yuzhi and Sai, B. and Yang, Lijuan and Shi, Qiong and Kuang, Y. and Yang, Zhe and Zhu, Yuechun}
}
Background: Clear cell renal cell carcinoma (ccRCC) is a cell metabolic disease with high metastasis rate and poor prognosis. Our previous studies demonstrate that glucose-6-phosphate dehydrogenase (G6PD), the first and rate-limiting enzyme of the pentose phosphate pathway, is highly expressed in ccRCC and predicts poor outcomes of ccRCC patients. The aims of this study were to confirm the oncogenic role of G6PD in ccRCC and unravels novel mechanisms involving Cyclin E1 and MMP9 in G6PD-mediated ccRCC progression. Methods: Real-time RT-PCR, Western blot and immunohistochemistry were used to determine the expression patterns of G6PD, Cyclin E1 and MMP9 in ccRCC. TCGA dataset mining was used to identify Cyclin E1 and MMP9 correlations with G6PD expression, relationships between clinicopathological characteristics of ccRCC and the genes of interest, as well as the prognosis of ccRCC patients. The role of G6PD in ccRCC progression and the regulatory effect of G6PD on Cyclin E1 and MMP9 expression were investigated by using a series of cytological function assays in vitro. To verify this mechanism in vivo, xenografted mice models were established. Results: G6PD, Cyclin E1 and MMP9 were overexpressed and positively correlated in ccRCC, and they were associated with poor prognosis of ccRCC patients. Moreover, G6PD changed cell cycle dynamics, facilitated cells proliferation, promoted migration in vitro, and enhanced ccRCC development in vivo, more likely through enhancing Cyclin E1 and MMP9 expression. Conclusion: These findings present G6PD, Cyclin E1 and MMP9, which contribute to ccRCC progression, as novel biomarkers and potential therapeutic targets for ccRCC treatment.
